Table 8.

Meta-analyses included for inflammatory bowel disease-related surgeries in ulcerative colitis

Study	Intervention	Comparator	Follow-up	N	Colectomy rate %, or OR (95% CI)	Quality of evidence
Komaki et al[28]	Tacrolimus	Placebo	2 wk (RCT)	103	0%	High
Narula et al[29]	IFX	Cyclosporine	3 mo (RCT)	385	26.6% (IFX); 26.4% (C) OR 1.00 (0.64-1.59)	Low
	IFX	Cyclosporine	3 mo (non RCT)	478	24.1% (IFX); 42.5% (C) OR 0.53 (0.22-1.28)	Very low
	IFX	Cyclosporine	12 mo (RCT)	415	34.4% (IFX); 40.8% (C) OR 0.76 (0.51-1.14)	Low
	IFX	Cyclosporine	12 mo (non RCT)	854	20.7% (IFX); 36.8% (C) OR 0.42 (0.22-0.83)	Very low

C: Cyclosporine; CI: Confidence interval; IFX: Infliximab; n: Number of patients; OR: Odds ratio; RCT: Randomized clinical trial.